Proliferative vitreoretinopathy (PVR) remains the most commonly observed failure in the surgery of rhegmatogenous retinal detachment (RRD), albeit substantial efforts have been taken to better understand and manage the condition in the past. Basic research indicates that proliferative vitreoretinopathy illustrates scarring - end-stage of wound healing process, which occurs post-retinal detachment surgery. Current medical treatment for PVR has been directed toward the prevention of inflammation – first stage of wound-healing process, and inhibition of cell proliferation – second stage.
Surgery for proliferative vitreoretinopathy, at present, demonstrates high anatomical success rate, despite disappointing visual results. Utilization of adjunctive treatments for preventing cellular proliferation has been deemed effective in the treatment & prevention of PVR, or post-surgery recurrences. Proliferation control and strategies directed toward the improvement of visual outcome are imperative focus areas for future studies in PVR. In addition, researches on the peri-retinal and intra-retinal pathology of proliferative vitreoretinopathy have illustrated characteristic alterations, which will significantly influence surgical management and visual outcome.
A recent Fact.MR report foresees the proliferative vitreoretinopathy market to record a moderate rise over the period of forecast (2018-2027). Revenues from treatment and management of proliferative vitreoretinopathy worldwide will reach nearly US$ 660 Mn by 2027-end.
Proliferative Vitreoretinopathy Market: Potential of Systemic Anti-TNFα Treatment in Reduction of PVR to Influence Future Developments
Lack of effective prophylaxis or treatment has made proliferative vitreoretinopathy one of the most devastating complications witnessed in RRD. TNFα has been implied in PVR development, which in turn necessitates blockade of this factor for reducing or preventing onset of proliferative vitreoretinopathy. However, systemic treatment of PVR using anti-TNFα entails several side-effects and risks, and employment of such drugs for PVR treatment is not yet justified. Researchers have sought indirect approaches for determination of effectiveness of anti-TNFα in protection against PVR development post-RRD surgery.
Despite sound principles on which the approaches are based, low prevalence of patients affected with RRD, chronic inflammatory diseases, and PVR has prevented researchers from drawing conclusions with regard to potential effectiveness of the anti-TNFα therapy as prophylactic treatment for preventing or reducing PVR incidences following RRD. However, these approaches hold promise in promoting future in-vivo studies, and randomizing clinical trials in humans with the help of more preclinical research.
Proliferative Vitreoretinopathy Market: New PVR Development Suppression & Prevention Methods to Underpin Growth
Proliferative vitreoretinopathy, an inflammatory fibrotic disease, stems from inflammatory milieu post-RRD, which in turn prevents retinal healing. Several studies aimed at suppressing or preventing the development of PVR are being conducted worldwide, with some of the recent ones elucidating effect of “substance P (SP),” and targeted use of non-steroidal anti-inflammatory drugs such as “lornoxicam.”
Research carried out on lornoxicam has not only demonstrated successful improvement in the condition of retina and choroid, but also reduced frequency of membrane formation significantly. Studies conducted on substance P have revealed that SP has the capability of inhibiting apoptosis, and epithelial-mesenchymal transition (EMT) induced by TNFα caused, thereby suppressing or preventing development of proliferative retinopathy.
Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR
The most frequent and traumatic complication faced post-rhegmatogenous retinal detachment (RRD), proliferative vitreoretinopathy (PVR) continues to be a bottleneck in developing new surgical techniques for diseases related to retina such as retinal pigment epithelium transplantation, and macular translocation. Posterior contraction of the membranes formed on either sides of retina that are a result of PVR, and shortening of retina are key complications that prevent reattachment of retina.
Complex vitreoretinal surgical techniques, which currently form the base for PVR management, are capable of achieving anatomical attachment in just 60-70% cases. Moreover, functional results are unsatisfactory, which in turn has led medical scientists to focus more on finding effective prophylaxis for prevention of PVR. Fact.MR’s recent analytical research report offers a 10-year forecast on proliferative vitreoretinopathy market for the period between 2018 and 2027. This holistic and exhaustive analysis on proliferative vitreoretinopathy market offers valuable insights and comprehensive assessment on key factors impacting the market growth.
Proliferative Vitreoretinopathy Market: Taxonomy
This report propounds quantitative & qualitative analyses on proliferative vitreoretinopathy market, providing complete view on the current as well as future market prospects. The value forecast rendered in this study is in terms of US$ Mn. Qualitative analysis offered illuminates microeconomic, industry-specific, and macroeconomic factors that are likely to impact future market expansion. This report embodies complete insights on prominent growth determinants, restraints, opportunities, and threats, which will potentially affect the market’s growth in the forthcoming years.
A segmentation-wise analysis and insights on proliferative vitreoretinopathy market has been issued, which enables the report readers in acquiring accurate and transparent intelligence. The report branches the proliferative vitreoretinopathy market based on distribution channel, mode of administration, drug class, and region.
Competitive Landscape Assessment
This research study examines business strategies employed by the leading participants in the proliferative retinopathy market, and issues comprehensive insights to enable established as well as emerging companies in devising effective and fact-based growth strategies. For report readers, the chapter on the market’s competitive landscape is of paramount importance, as they seek scrutinized & actionable insights into current and future market status quo. Leading companies operating in the proliferative vitreoretinopathy market, including Genentech, Inc., Regeneron Pharmaceuticals, Inc., and Allergan Plc, have been profiled in the report.
A scrutinized SWOT analysis is rendered in the report, which imparts the strengths, weaknesses, opportunities, & threats of the market players. Intelligence on new product development, and impact of regulatory changes, coupled mergers and acquisition activity of these market players is incorporated for perusal of report readers.
A tested & proven research approach is employed by analysts at Fact.MR for evaluating key industry dynamics and offering precise and authentic market intelligence. A blend of primary & secondary research has been implemented for offering estimates and forecasts on the proliferative vitreoretinopathy market. Secondary research forms initial phase of our research, wherein the analysts conduct extensive information mining by referring to up-to-date and verified data resources that include technical journals, regulatory and government published material, and independent studies, which forms the basis of the market estimates.
All the market estimates and forecast offered are further verified via an exhaustive primary research, wherein interviews are conducted with leading market participants, and industry experts. These comprehensive primary interviews aid in validating the information procured and gain significant industry insights, estimations and key developments.
Fact.MR offers custom research services that help clients to get specific research solutions
We are committed towards customer satisfaction and quality service.